Evidence map›Paper›PMID 32618252›Full record

Trial reportThe American journal of tropical medicine and hygiene2020

Prevalence of

Sandra Chishimba, Mulenga Mwenda, Brenda Mambwe, Conceptor Mulube, Victor Chalwe, Hawela Moonga, Busiku Hamainza, Elizabeth Chizema-Kawesha, Richard W Steketee, Gonzalo Domingo and 10 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of tropical medicine and hygiene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02329301 (Assessing the Effectiveness of Mass Drug Administration), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02329301 nacompletednot on this map

Assessing the Effectiveness of Mass Drug Administration (MDA) With Dihydroartemisinin + Piperaquine for Reducing Malaria Parasite Infection Prevalence and Incidence in Southern Province Zambia

TypeinterventionalSponsorPATHRan2014 to 2020Enrolled2,430ConditionsMalaria, Malaria, FalciparumArmsMDA with DHAp (Eurartesim), Focal MDA with DHAp (Eurartesim)
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Adherence to Mass Drug Administration with Dihydroartemisinin-Piperaquine andThe American journal of tropical medicine and hygiene · 2020
    Trial
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Sandra Chishimba1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Mulenga Mwenda1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Brenda Mambwe1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Conceptor Mulube1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Victor Chalwe2Zambia Ministry of Health Provincial Medical Office, Mansa, Zambia.
Hawela Moonga3National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.
Busiku Hamainza3National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.
Elizabeth Chizema-Kawesha3National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia.
Richard W Steketee4PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.
Gonzalo Domingo4PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.
Maya Fraser4PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.
Maria Kahn4PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.
Sampa Pal4PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.
Kafula Silumbe1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Ruben O Conner4PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Seattle, Washington.
Adam Bennett5Malaria Elimination Initiative, Global Health Group, University of California San Francisco, San Francisco, California.
Travis R Porter6Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Thomas P Eisele6Department of Tropical Medicine, Center for Applied Malaria Research and Evaluation, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
John M Miller1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
Daniel J Bridges1PATH Malaria Control and Elimination Partnership in Africa (MACEPA), Lusaka, Zambia.
National HIV/AIDS/STI/TB Council · ZMProgram for Appropriate Technology in Health · USMinistry of Health · ZMTulane University · USUniversity of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malaria burden in Zambia has significantly declined over the last decade because of improved coverage of several key malaria interventions (e.g., vector control, case management, bed net distributions, and enhanced surveillance/responses). Campaign-based mass drug administration (MDA) and focal MDA (fMDA) were assessed in a trial in Southern Province, Zambia, to identify its utility in elimination efforts. As part of the study, a longitudinal cohort was visited and tested (by PCR targeting the 18s rRNA and a

Indexed as

Plasmodium falciparumAntimalarialsArtemisininsDrug Therapy, CombinationHumansLongitudinal StudiesMalariaMalaria, FalciparumMass Drug AdministrationPiperazinesPrevalenceQuinolinesReal-Time Polymerase Chain ReactionZambiaAntimalarialsArtemisininsartenimolpiperaquinePiperazinesQuinolines

Identifiers

PMID32618252
PMCPMC7416980
OpenAlexW3039341554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.